Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| ARRY | Array BioPharma Inc. | -0.24% | 46.26 | 8.1% | $690.49m | |
| AMGN | Amgen Inc. | -0.23% | 177.06 | 1.3% | $495.97m | |
| CELG | Celgene Corporation | -0.72% | 90.87 | 1.3% | $431.27m | |
| GILD | Gilead Sciences, Inc. | -0.03% | 66.92 | 0.9% | $401.89m | |
| BIIB | Biogen Inc. | -0.91% | 229.44 | 1.3% | $372.09m | |
| ILMN | Illumina, Inc. | 0.20% | 302.90 | 3.5% | $354.87m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.35% | 299.42 | 2.6% | $268.31m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.48% | 123.41 | 2.0% | $197.95m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.49% | 154.00 | 14.7% | $197.25m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.56% | 177.14 | 1.9% | $181.72m | |
| A | Agilent Technologies, Inc. | -0.52% | 69.59 | 1.6% | $140.09m | |
| EXAS | Exact Sciences Corporation | 1.21% | 116.34 | 24.1% | $137.96m | |
| INCY | Incyte Corporation | 0.44% | 80.23 | 2.5% | $110.35m | |
| BLUE | Bluebird Bio, Inc. | 4.33% | 139.45 | 14.3% | $97.87m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.12% | 82.47 | 4.3% | $84.42m |
Company Profile
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.